Analyst Tracker/Brandon Couillard

Brandon Couillard

Q: How accurate are Brandon Couillard's stock ratings?

About 62% of Brandon's ratings were profitable over a one-year hold, with an average return of +11.8% per rating, measured by 13Foresight from historical prices.

Q: How is Brandon ranked?

Brandon Couillard is ranked #443 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Wells Fargo

Wall Street Analyst

★★★★☆

#443

on 13Foresight · ranked by our own returns

66%

Success Rate

+12.2%

Average Return

42 of 64 calls profitable · +5.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 66% of Brandon Couillard's ratings turned a profit when each position was held for 2 year — averaging +12.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Brandon's Stock Coverage 35 ratings · 2026-11-07

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
BIO Bio-Rad Laboratories	Sep 29, 2026	HOLD	Buy -3.2% avg upside 9 analysts	—	-1.5%	·
WGS GeneDx Holdings	Sep 29, 2026	HOLD	Strong Buy +22.6% avg upside 10 analysts	—	-15.4%	·
RVTY Revvity	Sep 29, 2026	HOLD	Buy -20.0% avg upside 25 analysts	—	+1.5%	·
NTRA Natera	Sep 29, 2026	HOLD	Strong Buy -13.2% avg upside 28 analysts	—	-24.8%	·
MYGN Myriad Genetics	Sep 29, 2026	HOLD	Sell +159.8% avg upside 24 analysts	—	+40.0%	·
MTD Mettler-Toledo	Sep 29, 2026	HOLD	Buy -26.0% avg upside 19 analysts	—	+12.0%	·
MRVI Maravai Lifesciences Holdings	Sep 29, 2026	HOLD	Strong Buy +99.6% avg upside 18 analysts	—	-8.8%	·
MLAB Mesa Laboratories	Sep 29, 2026	HOLD	Strong Buy +22.6% avg upside 5 analysts	—	-4.4%	·
GH Guardant Health	Sep 29, 2026	HOLD	Strong Buy -3.1% avg upside 33 analysts	—	-15.1%	·
DHR Danaher	Sep 29, 2026	HOLD	Strong Buy -4.4% avg upside 47 analysts	—	+2.0%	·
CDNA CareDx	Sep 29, 2026	HOLD	Buy -41.1% avg upside 18 analysts	—	+23.7%	·
BRKR Bruker	Sep 29, 2026	HOLD	Buy +4.9% avg upside 22 analysts	—	-10.0%	·
BLLN BillionToOne, Inc. Class A	Sep 29, 2026	HOLD	Strong Buy +12.2% avg upside 10 analysts	—	-3.6%	·
TMO Thermo Fisher	Jul 23, 2026	BUY	Strong Buy -5.2% avg upside 40 analysts	$615.00 11.82% Downside	+23.5%	·
TECH Bio-Techne	Jun 26, 2026	BUY	Hold +16.2% avg upside 21 analysts	$62.00 14.61% Downside	+2.5%	·
A Agilent	May 28, 2026	BUY	Strong Buy -8.1% avg upside 35 analysts	$160.00 8.43% Downside	+29.5%	·
WAT Waters	May 14, 2026	HOLD	Strong Buy -12.6% avg upside 31 analysts	$370.00 19.95% Downside	+37.9%	·
RGEN Repligen	Feb 25, 2026	BUY	Strong Buy +1.2% avg upside 25 analysts	$180.00 1.64% Upside	+8.7%	·
AVTR Avantor	Feb 13, 2026	BUY	Buy +4.5% avg upside 27 analysts	$14.00 12.72% Downside	+50.6%	·
CYRX CryoPort	Mar 13, 2024	BUY	Strong Buy -4.1% avg upside 15 analysts	$17.00 1.76% Downside	-45.5%	·
HSIC Henry Schein	Mar 06, 2024	HOLD	Buy +9.6% avg upside 25 analysts	$81.00 4.49% Downside	+3.0%	·
XRAY DENTSPLY SIRONA	Feb 29, 2024	BUY	Buy +182.3% avg upside 25 analysts	$37.50 293.53% Upside	-51.7%	·
NVST Envista Holdings	Feb 09, 2024	HOLD	Buy +27.3% avg upside 19 analysts	$23.00 2.10% Downside	+33.8%	·
ALGN Align Tech	Feb 01, 2024	BUY	Buy +89.9% avg upside 21 analysts	$325.00 116.89% Upside	-40.4%	·
TBIO Telesis Bio	Aug 11, 2023	BUY	Strong Buy +719900.1% avg upside 7 analysts	$72.00 719900.05% Upside	·	·
SDCCQ SmileDirectClub	May 10, 2023	HOLD	Sell +513999900.0% avg upside 10 analysts	$0.60 59999900.04% Upside	·	·
KEYS Keysight Technologies	Aug 29, 2022	BUY	Strong Buy +11.0% avg upside 17 analysts	$200.00 34.85% Downside	-8.1%	·
NAUT Nautilus Biotechnolgy	May 04, 2022	BUY	Strong Buy +321.2% avg upside 5 analysts	$11.00 302.95% Upside	-43.0%	·
CDXS Codexis	Jun 18, 2021	BUY	Strong Buy +746.3% avg upside 13 analysts	$26.00 2084.83% Upside	-87.0%	·
OSUR Orasure Technologies	Aug 06, 2020	HOLD	Buy +111.5% avg upside 12 analysts	$15.00 280.78% Upside	-75.8%	·
BDX Becton Dickinson	May 18, 2020	BUY	Buy -0.4% avg upside 25 analysts	$300.00 51.61% Upside	-0.1%	·
OPK Opko Health	Aug 08, 2018	HOLD	Strong Buy +284.6% avg upside 12 analysts	$4.50 171.12% Upside	+2.5%	·
VIVS VivoSim Labs	Jul 27, 2018	BUY	Buy +1759.6% avg upside 5 analysts	$1.75 1031.87% Upside	·	·
BMRN BioMarin Pharmaceutical	May 31, 2017	BUY	Strong Buy +63.6% avg upside 52 analysts	$116.00 98.25% Upside	-6.2%	·
QGEN Qiagen	Nov 22, 2016	HOLD	Buy -10.5% avg upside 25 analysts	$26.00 48.24% Downside	+23.9%	·

🔒 30 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Brandon Couillard — Frequently Asked Questions

How accurate are Brandon Couillard's stock ratings?

Based on the calls 13Foresight could measure, about 62% of Brandon's ratings were profitable over a one-year hold, with an average return of +11.8% per rating, or +7.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Brandon ranked on 13Foresight?

Brandon Couillard is currently ranked #443 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Brandon cover?

Brandon most recently has ratings on BIO, WGS, RVTY, NTRA, MYGN, MTD, MRVI, MLAB, GH, DHR, CDNA, BRKR and 23 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Brandon Couillard

Welcome to 13Foresight!